trending Market Intelligence /marketintelligence/en/news-insights/trending/VvBZZ_Xj_mwT2cHGjYqv4w2 content esgSubNav
In This List

US FDA approves Anika's bone repair treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves Anika's bone repair treatment

The U.S. Food and Drug Administration approved Anika Therapeutics, Inc.'s injectable bone repair treatment.

The U.S. regulator granted 510(k) clearance to the company's injectable hyaluronic acid-based bone void filler for filling bone voids or defects of the skeletal system.

The bone void filler is resorbed and replaced by the growth of new bone during the healing process.